2006-11-23T00:00:00
The National Institute for Health and Clinical Excellence has announced that it is recommending the use of the hormonal therapies anastrozole, exemestane and letrozole for the treatment of women with early oestrogen receptor-positive invasive breast cancer following surgery to remove the tumours.The drugs will be available alongside existing breast cancer ...
With a HSJ subscription you’ll unlock:
HSJ is part of Wilmington Healthcare Limited. Company number 2530185. c/o Wilmington plc, 5th Floor, 10 Whitechapel High Street, London E1 8QS. Registered in England and Wales. Company registration 30158470
Site powered by Webvision Cloud